Seattle Cancer Care Alliance Clinicians Present New Research at 63rd Annual Meeting of the American Society of Hematology

SEATTLE — December 9, 2021 — Seattle Cancer Care Alliance (SCCA), the only National Comprehensive Cancer Network (NCCN)-designated cancer center in Washington state, today announced that more than 20 of the organization’s clinicians will showcase new research at the 63rd Annual Meeting of the American Society of Hematology (ASH), taking place December 11-14, 2021, in Atlanta.

SCCA clinicians and researchers will unveil findings on areas of investigation into treatments for patients with various hematological malignancies, including lymphoma, leukemia and myeloma. Clinicians will discuss findings on CAR-T therapies targeting CD20 cells, multiple myeloma and chronic lymphocytic leukemia. Key research also includes findings on hematopoietic stem cell transplant (HCT) and outcomes and utilization for a range of treatments.

“Our team at Seattle Cancer Care Alliance is committed to understanding, developing and advancing cutting-edge cancer treatments,” said Nancy Davidson, MD, president and executive director of SCCA. “Our researchers and clinicians are known leaders in the hematological clinical research space; we are proud of their work and continued contributions to this space. We look forward to energized discussion on the implications of the research presented and the role the research plays in contributing to expanded treatment options for patients.”

 Below is a list of SCCA’s lead abstracts and presentations:

CAR-T Therapies:

Abstract: 3872 - Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL

Abstract: 2815 - Pharmacodynamic Analysis of CAR-T Cell Persistence in Patients with Hematologic Malignancies Treated with NKTR-255, an IL-15 Receptor Agonist That Enhances CD8+ T-Cells: Preliminary Results from a Phase 1 Study

Abstract: 1749 - Long-Term Follow-up and Single-Cell Multiomics Characteristics of Infusion Products in Patients with Chronic Lymphocytic Leukemia Treated with CD19 CAR-T Cells

Abstract: 551 - Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Abstract: 905 - Clinical Translation of SC-DARIC33: A Pharmacologically Controlled CD33-Targeted Anti-AML CAR T Cell Product Regulated By Low Nanomolar Concentrations of Rapamycin

Abstract: 470 - SCRI-CAR19x22v2 T Cell Product Demonstrates Bispecific Activity in B-ALL

Hematopoietic Stem Cell Transplant (HCT)

Abstract: 645 - Donor Bone Marrow Derived Macrophage Engraftment into the Central Nervous System of Allogeneic Transplant Patients

Abstract: 646 - Non-Genetic Determinants of Clonotypic T Cell Expansion Following Allogeneic Stem Cell Transplant

Abstract: 2868 - COVID-19 in Pediatric Hematopoietic Cell Transplant Recipients: A CIBMTR Study

Abstract: 648 - Early Cytomegalovirus Reactivation after Allogenic Bone Marrow Transplantation Is Associated with the Loss of Recipient-Derived Humoral Immunity and Is Reduced By IL-6 Inhibition

  • SCCA Author: Ping Zhang, MD

Treatments of Hematological Malignancies

Abstract: 1208 - The Efficacy and Safety of Low-Dose Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia: Interim Results of a Phase 4 Study

Abstract: 34 -  A Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Abstract: 813 -  Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203)

Abstract: 233 - Concurrent Pembrolizumab with AVD for Untreated Classical Hodgkin Lymphoma

Abstract: 1410 - Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies

Abstract: 1363 - Oral Ixazomib in Untreated Follicular Lymphoma Permits COVID-19 Vaccine Response and Its Efficacy Is Associated with Clinical Factors and Gene Expression Signatures

Abstract: 799 - Global Proteomic Profiling Identifies Novel Prognostic Factors in Undifferentiated Leukemia Blasts from Patients with NPM1 Mutations: A Previously Unreported Approach to Biomarker Discovery from the Fred Hutch and SWOG

Abstract: 403 - CD22 CAR Optimization for Improved in-Human Activity Following Inadequate CD22 CAR Activity in Phase 1 Clinical Trial PLAT-04

Abstract: 2339 - Infectious Complications after Intensive Chemotherapy with CLAG-M or ‘7+3’ for Adults with Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Abstract: 3341 - Development of Astatine-211 (211At)-Based Anti-CD123 Radioimmunotherapy for Acute Leukemias and Other CD123+ Hematologic Malignancies

Abstract: 2745 - TIG-007: Study of EOS884448/GSK4428859A Alone, and in Combination with Iberdomide with or without Dexamethasone, in Participants with Relapsed or Refractory Multiple Myeloma

Abstract: 3909 - Patient-Reported Outcomes (PROs) Among Patients with Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)

Abstract: 2094 - Absence of Hyperactivation of Fibrinolysis Explains the Lack of Hemostatic Efficacy of Prophylactic Tranexamic Acid (TXA) in Hypoproliferative Thrombocytopenia

  • SCCA Author: Terry B. Gernsheimer, MD

Abstract: 1609 - The IL-2/IL-15 Mimetic NL-201 Prevents Myeloma Relapse after ASCT By Expanding Highly Cytolytic T Cells in the Bone Marrow That Are Resistant to Exhaustion

  • SCCA Author: Simone A. Minnie, PhD

Abstract: 328 - The Combination of Anti-Tigit and Lenalidomide Promotes Synergistic Myeloma-Specific Immunity after ASCT

  • SCCA Author: Simone A. Minnie, PhD

Media Contact:
Fred Hutch Media Team